Meeting	Peninsula Cancer Alliance Board 29 January 2020
Title	MDT Modernisation
Author	Jonathan Miller, Cancer Alliance Manager
Agenda Item	5

# Summary

National guidance for modernising MDTs has been published (attached). The Alliance is proposing practical actions to implementing this guidance.

## Recommendation

The Board are asked to support the proposed approach to implementing this national guidance.



# Peninsula Cancer Alliance MDT Modernisation

## Introduction

The actions set out here are derived from the national guidance *Streamlining Multi-Disciplinary Team Meetings*.

"The key principle to achieve MDTM streamlining is that all patients remain listed and recorded at the MDTM, however patients will be stratified into two groups:

- 1. Those cases where full discussion at the MDTM is required, for example due to clinical complexity or psycho-social issues, and
- 2. Those cases where a patient's needs can be met by a standard treatment protocol (or Standard of Care), and so do not require discussion at the MDTM."

#### **Actions**

Topic	Action	Deadline
Standards	Each MDT will agree Standards of Care including details of	
of Care	which patients do not need discussion at the MDT.	
	These should be signed off by the Trust Medical Director and	
	lead cancer clinician.	
Standards	Standards of care will specify the diagnostic tests needed to	
of Care	asses treatment options. This should include the genomic	
	tests needed.	
Standards	Standards of Care should include clinical trials available as a	
of Care	treatment option.	
Standards	Standards of Care should be consistent with the agreed	
of Care	Alliance Site-Specific Group's Standard of Care.	
	All MDT have a responsibility to support the rapid agreement	
	of Standards of Care at Alliance Site Specific Groups.	
Pathways	A process for triage should be agreed at Trust level with approval	
	from the Medical Director before SoCs are used to remove the	
	need for an MDT discussion.	

Pathways  The following information must be recorded to list a patient not for discussion at the MDT:  Diagnosis date (specify mode of diagnosis) Stage (specify investigations) Performance status Histopathological and/or cytological diagnosis; Co-morbidities; Availability of, and suitability for, clinical trial/s; Relevant genomic/genetic testing11; Patient preference (if known) and/or any special circumstances have been taken into consideration MDT recommendation and treatment pathway; Any additional tumour-specific tests needed to inform diagnosis Molecular profiling as related to a particular cancer tumour Specific imaging protocols for a tumour site to ensure consistency of imaging across referral pathways Other fitness assessment parameters, e.g. frailty assessment, as per SoCs.  Pathways MDTs will revise pathways so that patients are only routinely discussed at one MDT prior to decision to treat (counting both local and specialist MDTs).  Pathways Consultants should be supported to get additional diagnostic tests and clinical opinions in a timely way without recourse to the MDT.  Pathways Where the Standard of Care indicates a specific treatment option, patients should be referred directly to the treating specialist without waiting for the MDT (local or specialist). This includes referral to specialists at other providers.  Where the Standard of Care indicates a need for discussion at a specialist MDT, patients should be referred directly to the Specialist MDT without waiting for a local MDT.  MDT MDT with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate? and support consultant professional development.  Radiologists and histopathologists will record their site specialisms in the Directory of Services  Diagnostic reporting for MDTs  Diagnostic tests (images or pathology) requested explicitly for cancer diagnosis should only be reported by a radiologist or histopathologist acredited as a specialist in tha	Topic	Action	Deadline
for discussion at the MDT:  Diagnosis date (specify mode of diagnosis) Stage (specify investigations) Performance status Histopathological and/or cytological diagnosis; Co-morbidities; Availability of, and suitability for, clinical trial/s; Patient preference (if known) and/or any special circumstances have been taken into consideration MDT recommendation and treatment pathway; Any additional tumour-specific tests needed to inform diagnosis Molecular profiling as related to a particular cancer tumour Specific imaging protocols for a tumour site to ensure consistency of imaging across referral pathways Other fitness assessment parameters, e.g. fraility assessment, as per SoCs.  Pathways MDTs will revise pathways so that patients are only routinely discussed at one MDT prior to decision to treat (counting both local and specialist MDT). Consultrants should be supported to get additional diagnostic tests and clinical opinions in a timely way without recourse to the MDT.  Where the Standard of Care indicates a specific treatment option, patients should be referred directly to the treating specialist MDT, patients should be referred directly to the specialist MDT in thou waiting for a local MDT.  Where the Standard of Care indicates a need for discussion at a specialist MDT without waiting for a local MDT.  MDT with more than one consultant in a treating speciality should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate <sup>2</sup> and support consultant professional development.  Diagnostic reporting for MDTs discusses tests (images or pathology) requested explicitly for cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic tests tests (images or pathology) requested explicitly for cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic tests rep		The following information must be recorded to list a patient not	
Stage (specify investigations) Performance status Histopathological and/or cytological diagnosis; Co-morbidities; Availability of, and suitability for, clinical trial/s; Relevant genomic/genetic testing11; Patient preference (if known) and/or any special circumstances have been taken into consideration MDT recommendation and treatment pathway; Any additional tumour-specific tests needed to inform diagnosis Molecular profiling as related to a particular cancer tumour Specific imaging protocols for a tumour site to ensure consistency of imaging across referral pathways Other fitness assessment parameters, e.g. frailty assessment, as per SoCs.  Pathways MDTs will revise pathways so that patients are only routinely discussed at one MDT prior to decision to treat (counting both local and specialist MDTs).  Pathways Consultants should be supported to get additional diagnostic tests and clinical opinions in a timely way without recourse to the MDT.  Where the Standard of Care indicates a specific treatment option, patients should be referred directly to the treating specialist without waiting for the MDT (local or specialist). This includes referral to specialists at other providers.  Where the Standard of Care indicates a need for discussion at a specialist MDT, patients should be referred directly to the Specialist MDT without waiting for a local MDT.  MDT MDT membership MDT with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Pathways in the Directory of Services Diagnostic reporting for MDTs Diagnostic reporting for biagnostic stests (images or pathology) requested explicitly for cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic reporting for biagnostic tests reported a radiologist or histopathologist accredited as a specialist in that canc			
Stage (specify investigations) Performance status Histopathological and/or cytological diagnosis; Co-morbidities; Availability of, and suitability for, clinical trial/s; Relevant genomic/genetic testing11; Patient preference (if known) and/or any special circumstances have been taken into consideration MDT recommendation and treatment pathway; Any additional tumour-specific tests needed to inform diagnosis Molecular profiling as related to a particular cancer tumour Specific imaging protocols for a tumour site to ensure consistency of imaging across referral pathways Other fitness assessment parameters, e.g. frailty assessment, as per SoCs.  Pathways MDTs will revise pathways so that patients are only routinely discussed at one MDT prior to decision to treat (counting both local and specialist MDTs).  Pathways Consultants should be supported to get additional diagnostic tests and clinical opinions in a timely way without recourse to the MDT.  Where the Standard of Care indicates a specific treatment option, patients should be referred directly to the treating specialist without waiting for the MDT (local or specialist). This includes referral to specialists at other providers.  Where the Standard of Care indicates a need for discussion at a specialist MDT, patients should be referred directly to the Specialist MDT without waiting for a local MDT.  MDT MDT membership MDT with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Pathways in the Directory of Services Diagnostic reporting for MDTs Diagnostic reporting for biagnostic stests (images or pathology) requested explicitly for cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic reporting for biagnostic tests reported a radiologist or histopathologist accredited as a specialist in that canc		Diagnosis date (specify mode of diagnosis)	
Performance status Histopathological and/or cytological diagnosis; Co-morbidities; Availability of, and suitability for, clinical trial/s; Relevant genomic/genetic testing11; Patient preference (if known) and/or any special circumstances have been taken into consideration MDT recommendation and treatment pathway; Any additional tumour-specific tests needed to inform diagnosis Molecular profiling as related to a particular cancer tumour Specific imaging protocols for a tumour site to ensure consistency of imaging across referral pathways Other fitness assessment parameters, e.g. frailty assessment, as per SoCs.  Pathways MDTs will revise pathways so that patients are only routinely discussed at one MDT prior to decision to treat (counting both local and specialist MDTs).  Pathways Consultants should be supported to get additional diagnostic tests and clinical opinions in a timely way without recourse to the MDT.  Pathways Where the Standard of Care indicates a specific treatment option, patients should be referred directly to the treating specialist without waiting for the MDT (local or specialist). This includes referral to specialists at other providers.  Where the Standard of Care indicates a need for discussion at a specialist MDT without waiting for a local MDT.  MDT MDT MDTs with more than one consultant in a treating speciality should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Diagnostic reporting for MDTs Diagnostic tests (images or pathology) requested explicitly for cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic reporting for biognostic tests reported a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic reporting for himpute the patient is referred to the Specialist or histopathologist accredited as a			
Histopathological and/or cytological diagnosis;     Co-morbidities;     Availability of, and suitability for, clinical trial/s;     Relevant genomic/genetic testing11;     Patient preference (if known) and/or any special circumstances have been taken into consideration     MDT recommendation and treatment pathway;     Any additional tumour-specific tests needed to inform diagnosis     Molecular profiling as related to a particular cancer tumour     Specific imaging protocols for a tumour site to ensure consistency of imaging across referral pathways     Other fitness assessment parameters, e.g. frailty assessment, as per SoCs.  Pathways     MDTs will revise pathways so that patients are only routinely discussed at one MDT prior to decision to treat (counting both local and specialist MDTs).  Pathways     Consultants should be supported to get additional diagnostic tests and clinical opinions in a timely way without recourse to the MDT.  Where the Standard of Care indicates a specific treatment option, patients should be referred directly to the treating specialist without waiting for the MDT (local or specialist). This includes referral to specialists at other providers.  Where the Standard of Care indicates a need for discussion at a specialist MDT, patients should be referred directly to the Specialist MDT without waiting for a local MDT.  MDT     MDTs with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Diagnostic reporting for MDTs  Diagnostic biagnostic tests (images or pathology) requested explicitly for cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic reporting for MDTs  Diagnostic reporting for MDTs  Diagnostic reporting for in the Directory of Services  Diagnostic reporting for pathology the pathologist accredited as a spec		, , , , , , , , , , , , , , , , , , , ,	
Co-morbidities; Availability of, and suitability for, clinical trial/s; Relevant genomic/genetic testing11; Patient preference (if known) and/or any special circumstances have been taken into consideration MDT recommendation and treatment pathway; Any additional tumour-specific tests needed to inform diagnosis Molecular profiling as related to a particular cancer tumour Specific imaging protocols for a tumour site to ensure consistency of imaging across referral pathways Other fitness assessment parameters, e.g. frailty assessment, as per SoCs.  Pathways MDTs will revise pathways so that patients are only routinely discussed at one MDT prior to decision to treat (counting both local and specialist MDTs).  Pathways Consultants should be supported to get additional diagnostic tests and clinical opinions in a timely way without recourse to the MDT.  Pathways Where the Standard of Care indicates a specific treatment option, patients should be referred directly to the treating specialist without waiting for the MDT (local or specialist). This includes referral to specialists at other providers.  Where the Standard of Care indicates a need for discussion at a specialist MDT, patients should be referred directly to the Specialist MDT without waiting for a local MDT.  MDT MDT with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Padiognostic reporting for MDTs  Diagnostic reporting for Indicates a specialist will record their site specialisms in the Directory of Services  Diagnostic reporting for Indicates a specialist in that cancer, as defined in the Directory of Services  Diagnostic reporting for Indicate as a specialist in that cancer, as defined in the Directory of Services  Diagnostic reporting for Indicate as a specialist in that cancer, as defined in the Directory of Services  Diagnostic reporting for Indicate as a specialist in that cancer, as defined in the			
Availability of, and suitability for, clinical trial/s;     Relevant genomic/genetic testing11;     Patient preference (if known) and/or any special circumstances have been taken into consideration     MDT recommendation and treatment pathway;     Any additional tumour-specific tests needed to inform diagnosis     Molecular profiling as related to a particular cancer tumour     Specific imaging protocols for a tumour site to ensure consistency of imaging across referral pathways     Other fitness assessment parameters, e.g. frailty assessment, as per SoCs.  Pathways  MDTs will revise pathways so that patients are only routinely discussed at one MDT prior to decision to treat (counting both local and specialist MDTs).  Pathways  Consultants should be supported to get additional diagnostic tests and clinical opinions in a timely way without recourse to the MDT.  Where the Standard of Care indicates a specific treatment option, patients should be referred directly to the treating specialist without waiting for the MDT (local or specialist). This includes referral to specialists at other providers.  Where the Standard of Care indicates a need for discussion at a specialist MDT patients should be referred directly to the Specialist MDT without waiting for a local MDT.  MDT  MDT  MDT with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Padiopostic reporting for MDTs  Diagnostic Radiologists and histopathologists will record their site specialisms in the Directory of Services  Diagnostic reporting for MDTs  Diagnostic reporting for ADTs  Diagnostic reportin		, , , , , , , , , , , , , , , , , , , ,	
Relevant genomic/genetic testing11; Patient preference (if known) and/or any special circumstances have been taken into consideration MDT recommendation and treatment pathway; Any additional tumour-specific tests needed to inform diagnosis Molecular profiling as related to a particular cancer tumour Specific imaging protocols for a tumour site to ensure consistency of imaging across referral pathways Other fitness assessment parameters, e.g. frailty assessment, as per SoCs.  Pathways MDTs will revise pathways so that patients are only routinely discussed at one MDT prior to decision to treat (counting both local and specialist MDTs).  Consultants should be supported to get additional diagnostic tests and clinical opinions in a timely way without recourse to the MDT.  Pathways Where the Standard of Care indicates a specific treatment option, patients should be referred directly to the treating specialist without waiting for the MDT (local or specialist). This includes referral to specialists at other providers.  Where the Standard of Care indicates a need for discussion at a specialist MDT, patients should be referred directly to the Specialist MDT without waiting for a local MDT.  MDT  MDT  MDT  MDT  MDT  MDT  MDT		·	
Patient preference (if known) and/or any special circumstances have been taken into consideration  MDT recommendation and treatment pathway; Any additional tumour-specific tests needed to inform diagnosis Molecular profiling as related to a particular cancer tumour Specific imaging protocols for a tumour site to ensure consistency of imaging across referral pathways Other fitness assessment parameters, e.g. frailty assessment, as per SoCs.  Pathways  MDTs will revise pathways so that patients are only routinely discussed at one MDT prior to decision to treat (counting both local and specialist MDTs).  Pathways  Consultants should be supported to get additional diagnostic tests and clinical opinions in a timely way without recourse to the MDT.  Where the Standard of Care indicates a specific treatment option, patients should be referred directly to the treating specialist without waiting for the MDT (local or specialist). This includes referral to specialists at other providers.  Where the Standard of Care indicates a need for discussion at a specialist MDT without waiting for a local MDT.  MDT without waiting for a local MDT.  MDTs with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Radiologists and histopathologists will record their site specialisms in the Directory of Services  Diagnostic reporting for MDTs  Diagnostic reporting for a local MDT.  Diagnostic reporting for Additional diagnostic re			
circumstances have been taken into consideration  MDT recommendation and treatment pathway;  Any additional tumour-specific tests needed to inform diagnosis  Molecular profiling as related to a particular cancer tumour  Specific imaging protocols for a tumour site to ensure consistency of imaging across referral pathways  Other fitness assessment parameters, e.g. frailty assessment, as per SoCs.  Pathways  MDTs will revise pathways so that patients are only routinely discussed at one MDT prior to decision to treat (counting both local and specialist MDTs).  Pathways  Consultants should be supported to get additional diagnostic tests and clinical opinions in a timely way without recourse to the MDT.  Where the Standard of Care indicates a specific treatment option, patients should be referred directly to the treating specialist without waiting for the MDT (local or specialist). This includes referral to specialists at other providers.  Where the Standard of Care indicates a need for discussion at a specialist MDT, patients should be referred directly to the Specialist MDT, patients should be referred directly to the Specialist MDT without waiting for a local MDT.  MDT  MDT  MDT  MDTs with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Diagnostic reporting for MDTs  Diagnostic reported - even if that specialist is a member of the Local MDT and the patient is referred to the Specialist			
MDT recommendation and treatment pathway;     Any additional tumour-specific tests needed to inform diagnosis     Molecular profiling as related to a particular cancer tumour     Specific imaging protocols for a tumour site to ensure consistency of imaging across referral pathways     Other fitness assessment parameters, e.g. frailty assessment, as per SoCs.  Pathways  MDTs will revise pathways so that patients are only routinely discussed at one MDT prior to decision to treat (counting both local and specialist MDTs).  Pathways  Consultants should be supported to get additional diagnostic tests and clinical opinions in a timely way without recourse to the MDT.  Where the Standard of Care indicates a specific treatment option, patients should be referred directly to the treating specialist without waiting for the MDT (local or specialist). This includes referral to specialists at other providers.  Where the Standard of Care indicates a need for discussion at a specialist MDT, patients should be referred directly to the Specialist MDT without waiting for a local MDT.  MDT  MDT without waiting for a local MDT.  MDTs with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Diagnostic reporting for MDTs  Diagnostic reported — even if that specialist in that cancer, as defined in the Directory of Services  Diagnostic reported — even if that specialist in a member of the Local MDT and the patient is referred to the Specialist			
Any additional tumour-specific tests needed to inform diagnosis     Molecular profiling as related to a particular cancer tumour     Specific imaging protocols for a tumour site to ensure consistency of imaging across referral pathways     Other fitness assessment parameters, e.g. frailty assessment, as per SoCs.  Pathways  MDTs will revise pathways so that patients are only routinely discussed at one MDT prior to decision to treat (counting both local and specialist MDTs).  Pathways  Consultants should be supported to get additional diagnostic tests and clinical opinions in a timely way without recourse to the MDT.  Where the Standard of Care indicates a specific treatment option, patients should be referred directly to the treating specialist without waiting for the MDT (local or specialist). This includes referral to specialists at other providers.  Where the Standard of Care indicates a need for discussion at a specialist MDT, patients should be referred directly to the Specialist MDT without waiting for a local MDT.  MDT  MDT without waiting for a local MDT.  MDTs with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Padiologists and histopathologists will record their site specialisms in the Directory of Services  Diagnostic reporting for MDTs  Diagnostic reporting for ADT and the patient is referred to the Specialist member of the Local MDT and the patient is referred to the Specialist			
diagnosis  • Molecular profiling as related to a particular cancer tumour  • Specific imaging protocols for a tumour site to ensure consistency of imaging across referral pathways  • Other fitness assessment parameters, e.g. frailty assessment, as per SoCs.  Pathways  MDTs will revise pathways so that patients are only routinely discussed at one MDT prior to decision to treat (counting both local and specialist MDTs).  Pathways  Consultants should be supported to get additional diagnostic tests and clinical opinions in a timely way without recourse to the MDT.  Pathways  Where the Standard of Care indicates a specific treatment option, patients should be referred directly to the treating specialist without waiting for the MDT (local or specialist). This includes referral to specialists at other providers.  Where the Standard of Care indicates a need for discussion at a specialist MDT, patients should be referred directly to the Specialist MDT without waiting for a local MDT.  MDT  MDT with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Padiologists and histopathologists will record their site specialisms in the Directory of Services  Diagnostic reporting for MDTs  Diagnostic cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic reporting for MDTs  Diagnostic stests reported a radiologist or histopathologist accredited as a specialist in that cancer should not be routinely re-reported – even if that specialist is a member of the Local MDT and the patient is referred to the Specialist			
Molecular profiling as related to a particular cancer tumour     Specific imaging protocols for a tumour site to ensure consistency of imaging across referral pathways     Other fitness assessment parameters, e.g. frailty assessment, as per SoCs.  Pathways  MDTs will revise pathways so that patients are only routinely discussed at one MDT prior to decision to treat (counting both local and specialist MDTs).  Pathways  Consultants should be supported to get additional diagnostic tests and clinical opinions in a timely way without recourse to the MDT.  Pathways  Where the Standard of Care indicates a specific treatment option, patients should be referred directly to the treating specialist without waiting for the MDT (local or specialist). This includes referral to specialists at other providers.  Where the Standard of Care indicates a need for discussion at a specialist MDT, patients should be referred directly to the Specialist MDT without waiting for a local MDT.  MDT MDTs with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Diagnostic Radiologists and histopathologists will record their site specialisms in the Directory of Services  Diagnostic reporting for MDTs  Diagnostic tests (images or pathology) requested explicitly for cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostics tests reported a radiologist or histopathologist accredited as a specialist in that cancer should not be routinely re-reported — even if that specialist is a member of the Local MDT and the patient is referred to the Specialist		· · · · · · · · · · · · · · · · · · ·	
tumour  • Specific imaging protocols for a tumour site to ensure consistency of imaging across referral pathways  • Other fitness assessment parameters, e.g. frailty assessment, as per SoCs.  Pathways  MDTs will revise pathways so that patients are only routinely discussed at one MDT prior to decision to treat (counting both local and specialist MDTs).  Pathways  Consultants should be supported to get additional diagnostic tests and clinical opinions in a timely way without recourse to the MDT.  Pathways  Where the Standard of Care indicates a specific treatment option, patients should be referred directly to the treating specialist without waiting for the MDT (local or specialist). This includes referral to specialists at other providers.  Where the Standard of Care indicates a need for discussion at a specialist MDT, patients should be referred directly to the Specialist MDT without waiting for a local MDT.  MDT  MDT MDTs with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Diagnostic reporting for MDTs  Diagnostic tests (images or pathology) requested explicitly for cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic reporting for MDTs  Diagnostics tests reported a radiologist or histopathologist accredited as a specialist in that cancer should not be routinely re-reported — even if that specialist is a member of the Local MDT and the patient is referred to the Specialist			
Specific imaging protocols for a tumour site to ensure consistency of imaging across referral pathways     Other fitness assessment parameters, e.g. frailty assessment, as per SoCs.  Pathways  MDTs will revise pathways so that patients are only routinely discussed at one MDT prior to decision to treat (counting both local and specialist MDTs).  Pathways  Consultants should be supported to get additional diagnostic tests and clinical opinions in a timely way without recourse to the MDT.  Pathways  Where the Standard of Care indicates a specific treatment option, patients should be referred directly to the treating specialist without waiting for the MDT (local or specialist). This includes referral to specialists at other providers.  Where the Standard of Care indicates a need for discussion at a specialist MDT, patients should be referred directly to the Specialist MDT without waiting for a local MDT.  MDT  MDT with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Diagnostic reporting for MDTs  Diagnostic reporting for a MDTs  Diagnostic reporting for MDTs  Diagnost		, , ,	
consistency of imaging across referral pathways			
Other fitness assessment parameters, e.g. frailty assessment, as per SoCs.  Pathways  MDTs will revise pathways so that patients are only routinely discussed at one MDT prior to decision to treat (counting both local and specialist MDTs).  Pathways  Consultants should be supported to get additional diagnostic tests and clinical opinions in a timely way without recourse to the MDT.  Pathways  Where the Standard of Care indicates a specific treatment option, patients should be referred directly to the treating specialist without waiting for the MDT (local or specialist). This includes referral to specialists at other providers.  Where the Standard of Care indicates a need for discussion at a specialist MDT, patients should be referred directly to the Specialist MDT without waiting for a local MDT.  MDT  MDTs with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Diagnostic reporting for MDTs  Diagnostic Diagnostics tests (images or pathology) requested explicitly for cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic reporting for MDTs  Diagnostic tests reported a radiologist or histopathologist accredited as a specialist in that cancer should not be routinely re-reported — even if that specialist is a member of the Local MDT and the patient is referred to the Specialist			
Pathways  MDTs will revise pathways so that patients are only routinely discussed at one MDT prior to decision to treat (counting both local and specialist MDTs).  Pathways  Consultants should be supported to get additional diagnostic tests and clinical opinions in a timely way without recourse to the MDT.  Pathways  Where the Standard of Care indicates a specific treatment option, patients should be referred directly to the treating specialist without waiting for the MDT (local or specialist). This includes referral to specialists at other providers.  Where the Standard of Care indicates a need for discussion at a specialist MDT, patients should be referred directly to the Specialist MDT, patients should be referred directly to the specialist MDT without waiting for a local MDT.  MDT  MDTs with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Diagnostic Radiologists and histopathologists will record their site specialisms in the Directory of Services  MDTs  Diagnostic Diagnostics tests (images or pathology) requested explicitly for cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic reporting for MDTs  Diagnostic rests reported a radiologist or histopathologist accredited as a specialist in that cancer should not be routinely re-reported — even if that specialist is a member of the Local MDT and the patient is referred to the Specialist			
Pathways  MDTs will revise pathways so that patients are only routinely discussed at one MDT prior to decision to treat (counting both local and specialist MDTs).  Pathways  Consultants should be supported to get additional diagnostic tests and clinical opinions in a timely way without recourse to the MDT.  Pathways  Where the Standard of Care indicates a specific treatment option, patients should be referred directly to the treating specialist without waiting for the MDT (local or specialist). This includes referral to specialists at other providers.  Where the Standard of Care indicates a need for discussion at a specialist MDT, patients should be referred directly to the Specialist MDT without waiting for a local MDT.  MDT  MDTs with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Diagnostic reporting for MDTs  Diagnostic Diagnostics tests (images or pathology) requested explicitly for cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic reporting for MDTs  Diagnostic reported as a specialist in that cancer, as defined in the Directory of Services  Diagnostics tests reported a radiologist or histopathologist accredited as a specialist in that cancer should not be routinely re-reported — even if that specialist is a member of the Local MDT and the patient is referred to the Specialist		, , , , , , , , , , , , , , , , , , , ,	
discussed at one MDT prior to decision to treat (counting both local and specialist MDTs).  Pathways  Consultants should be supported to get additional diagnostic tests and clinical opinions in a timely way without recourse to the MDT.  Pathways  Where the Standard of Care indicates a specific treatment option, patients should be referred directly to the treating specialist without waiting for the MDT (local or specialist). This includes referral to specialists at other providers.  Where the Standard of Care indicates a need for discussion at a specialist MDT, patients should be referred directly to the Specialist MDT without waiting for a local MDT.  MDT  MDTs with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Radiologists and histopathologists will record their site specialisms in the Directory of Services  Diagnostic reporting for MDTs  Diagnostic accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic reporting for MDTs  Diagnostic sets reported as a specialist in that cancer, as defined in the Directory of Services  Diagnostics tests reported a radiologist or histopathologist accredited as a specialist in that cancer should not be routinely re-reported — even if that specialist is a member of the Local MDT and the patient is referred to the Specialist	Dethyrore		
Pathways Consultants should be supported to get additional diagnostic tests and clinical opinions in a timely way without recourse to the MDT.  Pathways Where the Standard of Care indicates a specific treatment option, patients should be referred directly to the treating specialist without waiting for the MDT (local or specialist). This includes referral to specialists at other providers.  Where the Standard of Care indicates a need for discussion at a specialist MDT, patients should be referred directly to the Specialist MDT without waiting for a local MDT.  MDT MDTs with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Padiologists and histopathologists will record their site specialisms in the Directory of Services  Diagnostic reporting for MDTs  Diagnostic Diagnostics tests (images or pathology) requested explicitly for cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic reporting for MDTs  Diagnostic sets reported a radiologist or histopathologist accredited as a specialist in that cancer should not be routinely re-reported — even if that specialist is a member of the Local MDT and the patient is referred to the Specialist	Pairiways		
Pathways  Consultants should be supported to get additional diagnostic tests and clinical opinions in a timely way without recourse to the MDT.  Pathways  Where the Standard of Care indicates a specific treatment option, patients should be referred directly to the treating specialist without waiting for the MDT (local or specialist). This includes referral to specialists at other providers.  Where the Standard of Care indicates a need for discussion at a specialist MDT, patients should be referred directly to the Specialist MDT without waiting for a local MDT.  MDT  MDTs with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Diagnostic reporting for MDTs  Diagnostic Diagnostics tests (images or pathology) requested explicitly for cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic reporting for MDTs  Diagnostic Diagnostics tests reported a radiologist or histopathologist accredited as a specialist in that cancer should not be routinely re-reported – even if that specialist is a member of the Local MDT and the patient is referred to the Specialist			
tests and clinical opinions in a timely way without recourse to the MDT.  Pathways  Where the Standard of Care indicates a specific treatment option, patients should be referred directly to the treating specialist without waiting for the MDT (local or specialist). This includes referral to specialists at other providers.  Where the Standard of Care indicates a need for discussion at a specialist MDT, patients should be referred directly to the Specialist MDT without waiting for a local MDT.  MDT  MDTs with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Diagnostic reporting for MDTs  Diagnostic reporting for MDTs  Diagnostic reporting for MDTs  Diagnostic reporting for MDTs  Diagnostic Diagnostics tests (images or pathology) requested explicitly for cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostics tests reported a radiologist or histopathologist accredited as a specialist in that cancer should not be routinely re-reported — even if that specialist is a member of the Local MDT and the patient is referred to the Specialist	Dothwovo		
the MDT.  Pathways  Where the Standard of Care indicates a specific treatment option, patients should be referred directly to the treating specialist without waiting for the MDT (local or specialist). This includes referral to specialists at other providers.  Where the Standard of Care indicates a need for discussion at a specialist MDT, patients should be referred directly to the Specialist MDT without waiting for a local MDT.  MDT  MDTs with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Diagnostic reporting for MDTs  Diagnostic reporting for MDTs  Diagnostic reporting for MDTs  Diagnostic Diagnostics tests (images or pathology) requested explicitly for cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostics tests reported a radiologist or histopathologist accredited as a specialist in that cancer should not be routinely re-reported — even if that specialist is a member of the Local MDT and the patient is referred to the Specialist	Falliways		
Pathways  Where the Standard of Care indicates a specific treatment option, patients should be referred directly to the treating specialist without waiting for the MDT (local or specialist). This includes referral to specialists at other providers.  Where the Standard of Care indicates a need for discussion at a specialist MDT, patients should be referred directly to the Specialist MDT without waiting for a local MDT.  MDT  MDTs with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Diagnostic reporting for MDTs  Diagnostic patients and histopathologists will record their site specialisms in the Directory of Services  Diagnostic cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic reporting for Diagnostics tests reported a radiologist or histopathologist accredited as a specialist in that cancer should not be routinely re-reported — even if that specialist is a member of the Local MDT and the patient is referred to the Specialist		l	
option, patients should be referred directly to the treating specialist without waiting for the MDT (local or specialist). This includes referral to specialists at other providers.  Where the Standard of Care indicates a need for discussion at a specialist MDT, patients should be referred directly to the Specialist MDT without waiting for a local MDT.  MDT MDTs with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Diagnostic reporting for MDTs  Diagnostic reporting for MDTs  Diagnostic cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic reporting for MDTs  Diagnostic reporting for MDTs  Diagnostic reporting for defined in the Directory of Services  Diagnostic reporting for MDTs  Diagnostic reported — even if that specialist is a member of the Local MDT and the patient is referred to the Specialist	Pathways		
specialist without waiting for the MDT (local or specialist). This includes referral to specialists at other providers.  Where the Standard of Care indicates a need for discussion at a specialist MDT, patients should be referred directly to the Specialist MDT without waiting for a local MDT.  MDT  MDTs with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Diagnostic reporting for MDTs  Diagnostic reporting for MDTs  Diagnostics tests (images or pathology) requested explicitly for cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostics tests reported a radiologist or histopathologist accredited as a specialist in that cancer should not be routinely re-reported – even if that specialist is a member of the Local MDT and the patient is referred to the Specialist	1 alliways		
includes referral to specialists at other providers.  Where the Standard of Care indicates a need for discussion at a specialist MDT, patients should be referred directly to the Specialist MDT without waiting for a local MDT.  MDT MDTs with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Diagnostic reporting for MDTs  Diagnostic reporting for Cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic reporting for Cancer diagnosis tests reported a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic reporting for Cancer diagnostics tests reported a radiologist or histopathologist accredited as a specialist in that cancer should not be routinely re-reported — even if that specialist is a member of the Local MDT and the patient is referred to the Specialist		, · · · ·	
Where the Standard of Care indicates a need for discussion at a specialist MDT, patients should be referred directly to the Specialist MDT without waiting for a local MDT.  MDT  MDTs with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Diagnostic reporting for MDTs  Diagnostic Diagnostics tests (images or pathology) requested explicitly for cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic reporting for Diagnostics tests reported a radiologist or histopathologist accredited as a specialist in that cancer should not be routinely re-reported – even if that specialist is a member of the Local MDT and the patient is referred to the Specialist			
a specialist MDT, patients should be referred directly to the Specialist MDT without waiting for a local MDT.  MDTs with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Diagnostic reporting for MDTs  Diagnostic Diagnostics tests (images or pathology) requested explicitly for cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic reporting for MDTs  Diagnostic Diagnostics tests reported a radiologist or histopathologist accredited as a specialist in that cancer should not be routinely re-reported – even if that specialist is a member of the Local MDT and the patient is referred to the Specialist		infordade referral to opposituate at earler previousle.	
a specialist MDT, patients should be referred directly to the Specialist MDT without waiting for a local MDT.  MDTs with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Diagnostic reporting for MDTs  Diagnostic Diagnostics tests (images or pathology) requested explicitly for cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic reporting for MDTs  Diagnostic Diagnostics tests reported a radiologist or histopathologist accredited as a specialist in that cancer should not be routinely re-reported – even if that specialist is a member of the Local MDT and the patient is referred to the Specialist		Where the Standard of Care indicates a need for discussion at	
MDT MDTs with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Diagnostic reporting for MDTs  Diagnostic Diagnostics tests (images or pathology) requested explicitly for cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic reporting for MDTs  Diagnostic Tologophy and the Directory of Services  Diagnostic Tologophy			
MDT MDTs with more than one consultant in a treating specialty should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Diagnostic Radiologists and histopathologists will record their site specialisms in the Directory of Services  Diagnostic Diagnostics tests (images or pathology) requested explicitly for cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic Diagnostics tests reported a radiologist or histopathologist accredited as a specialist in that cancer should not be routinely re-reported — even if that specialist is a member of the Local MDT and the patient is referred to the Specialist			
membership should review scheduled MDT meeting attendance to identify the minimum attendance needed to be quorate² and support consultant professional development.  Diagnostic reporting for MDTs  Diagnostic reporting for MDTs  Diagnostic reporting for MDTs  Diagnostic reporting for MDTs  Diagnostics tests (images or pathology) requested explicitly for cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic reporting for Diagnostics tests reported a radiologist or histopathologist accredited as a specialist in that cancer should not be routinely re-reported — even if that specialist is a member of the Local MDT and the patient is referred to the Specialist	MDT		
the minimum attendance needed to be quorate² and support consultant professional development.  Diagnostic reporting for MDTs  Diagnostic reported Diagnostic stests (images or pathology) requested explicitly for cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic reporting for MDTs  Diagnostics tests reported a radiologist or histopathologist accredited as a specialist in that cancer should not be routinely re-reported — even if that specialist is a member of the Local MDT and the patient is referred to the Specialist			
Consultant professional development.  Diagnostic reporting for MDTs  Diagnostic Diagnostics tests (images or pathology) requested explicitly for cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic reporting for Diagnostics tests reported a radiologist or histopathologist accredited as a specialist or histopathologist accredited as a specialist or histopathologist accredited as a specialist in that cancer should not be routinely re-reported – even if that specialist is a member of the Local MDT and the patient is referred to the Specialist	,	,	
Diagnostic reporting for MDTs  Diagnostic reporting for MDTs  Diagnostic reporting for reporting for Earlier E			
reporting for MDTs  Diagnostic Diagnostics tests (images or pathology) requested explicitly for cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic Diagnostics tests reported a radiologist or histopathologist accredited as a specialist in that cancer should not be routinely re-reported – even if that specialist is a member of the Local MDT and the patient is referred to the Specialist	Diagnostic		
Diagnostic peorting for cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic peorting for Diagnostics tests reported a radiologist or histopathologist accredited as a specialist in that cancer should not be routinely re-reported – even if that specialist is a member of the Local MDT and the patient is referred to the Specialist	_		
reporting for MDTs cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic Diagnostics tests reported a radiologist or histopathologist accredited as a specialist in that cancer should not be routinely re-reported – even if that specialist is a member of the Local MDT and the patient is referred to the Specialist		•	
reporting for MDTs cancer diagnosis should only be reported by a radiologist or histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic Diagnostics tests reported a radiologist or histopathologist accredited as a specialist in that cancer should not be routinely re-reported – even if that specialist is a member of the Local MDT and the patient is referred to the Specialist	Diagnostic	Diagnostics tests (images or pathology) requested explicitly for	
MDTs histopathologist accredited as a specialist in that cancer, as defined in the Directory of Services  Diagnostic reporting for MDTs Diagnostics tests reported a radiologist or histopathologist accredited as a specialist in that cancer should not be routinely re-reported – even if that specialist is a member of the Local MDT and the patient is referred to the Specialist	_		
Diagnostic Diagnostics tests reported a radiologist or histopathologist accredited as a specialist in that cancer should not be routinely re-reported – even if that specialist is a member of the Local MDT and the patient is referred to the Specialist		, , , , , , , , , , , , , , , , , , , ,	
Diagnostic reporting for MDTs  Diagnostics tests reported a radiologist or histopathologist accredited as a specialist in that cancer should not be routinely re-reported – even if that specialist is a member of the Local MDT and the patient is referred to the Specialist		, , , , , , , , , , , , , , , , , , , ,	
reporting for MDTs accredited as a specialist in that cancer should not be routinely re-reported – even if that specialist is a member of the Local MDT and the patient is referred to the Specialist	Diagnostic		
MDTs routinely re-reported – even if that specialist is a member of the Local MDT and the patient is referred to the Specialist	_		
the Local MDT and the patient is referred to the Specialist			
MDT.			
		MDT.	

Topic	Action	Deadline
Audit	MDTs should review a sample of patient data quarterly, covering both patients on predetermined Standards of Care, and those referred for discussion at the MDT.	

#### **Notes**

- 1. The Alliance will support MDTs and Site-specific group by sharing local and national Standards of Care as they are agreed
- 2. Quality Surveillance Standards only require one consultant (or cover) from each treating specialty<sup>1</sup> to be present at an MDT to make the MDT quorate.

<sup>1</sup> Surgical Specialty, Clinical Oncology or Medical Oncology